- Home
- OBDC vs PTGX Comparison
OBDC vs PTGX Comparison
Compare OBDC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBDC | PTGX |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.4B |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | OBDC | PTGX |
|---|---|---|
| Price | $12.62 | $88.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $14.50 | ★ $90.56 |
| AVG Volume (30 Days) | ★ 4.8M | 1.1M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 12.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.39 | 0.72 |
| Revenue | ★ $1,797,946,000.00 | $209,217,000.00 |
| Revenue This Year | $19.12 | N/A |
| Revenue Next Year | N/A | $296.47 |
| P/E Ratio | ★ $9.10 | $121.37 |
| Revenue Growth | ★ 11.43 | N/A |
| 52 Week Low | $11.65 | $33.70 |
| 52 Week High | $15.73 | $96.54 |
Technical Indicators
Market Signals| Indicator | OBDC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 52.90 |
| Support Level | $12.92 | $84.11 |
| Resistance Level | $13.15 | $96.54 |
| Average True Range (ATR) | 0.21 | 3.37 |
| MACD | -0.08 | -0.86 |
| Stochastic Oscillator | 6.57 | 33.91 |
Price Performance
Historical ComparisonAbout OBDC Blue Owl Capital Corporation
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.